An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agents

Bull Cancer. 2017 Apr;104(4):385-387. doi: 10.1016/j.bulcan.2016.12.006. Epub 2017 Jan 26.
No abstract available

Keywords: Adénocarcinome pulmonaire; Afatinib; Anti-EGFR; Carcinomatose leptoméningée; Erlotinib; Leptomeningeal carcinomatosis; Lung adenocarcinoma.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenocarcinoma / diagnostic imaging
  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / secondary
  • Afatinib
  • Antineoplastic Agents / administration & dosage*
  • Carcinoma, Non-Small-Cell Lung / diagnostic imaging
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / secondary
  • ErbB Receptors / antagonists & inhibitors*
  • ErbB Receptors / genetics
  • Erlotinib Hydrochloride / administration & dosage*
  • Gefitinib
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / pathology
  • Male
  • Meningeal Carcinomatosis / diagnostic imaging
  • Meningeal Carcinomatosis / drug therapy*
  • Meningeal Carcinomatosis / secondary
  • Middle Aged
  • Quinazolines / administration & dosage

Substances

  • Antineoplastic Agents
  • Quinazolines
  • Afatinib
  • Erlotinib Hydrochloride
  • ErbB Receptors
  • Gefitinib